Cargando…
TB-04 TERT PROMOTER MUTATION AS A SUSCEPTIBLE MOLECULAR MARKER OF BCNU LOCAL THERAPY
INTRODUCTION: Alkylating agents, including Temozolomide (TMZ) and CCNU (ACNU) have been widely accepted as a standard treatment in malignant gliomas. Several studies also demonstrated that BCNU wafer placement extended survival in glioblastoma patients. However, little study demonstrated gene-specif...
Autores principales: | Miyake, Shigeta, Tateishi, Kensuke, Sasame, Joe, Miyake, Yohei, Matsuyama, Shinichirou, Nakamura, Taishi, Yamamoto, Tetsuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213408/ http://dx.doi.org/10.1093/noajnl/vdz039.047 |
Ejemplares similares
-
HGG-51. PAIRED EPITHELIOID GLIOBLASTOMA PATIENT DERIVED XENOGRAFT MODELS WITH/WITHOUT MOLECULAR TARGET THERAPY
por: Sasame, Jo, et al.
Publicado: (2020) -
BT-07 PATIENT DERIVED XENOGRAFT MODELS OF EPITHELIOID GLIOBLASTOMA AND THERAPEUTIC VULNERABILITY IN MOLECULAR TARGET THERAPY
por: Sasame, Jo, et al.
Publicado: (2019) -
TB-02 NF-KB CANONICAL PATHWAY ACTIVATION DRIVES GLYCOLYSIS AND TUMOR PROGRESSION IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
por: Tateishi, Kensuke, et al.
Publicado: (2019) -
CBMS-04 Novel xenograft model to clarify tumor progressive mechanism and therapeutic target in primary central nervous system lymphoma
por: Tateishi, Kensuke, et al.
Publicado: (2020) -
SPDR-01 Paired epithelioid glioblastoma patient-derived xenograft models to evaluate resistant mechanism for molecular target therapy
por: Sasame, Jo, et al.
Publicado: (2020)